Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Disrupted uromodulin trafficking is rescued by targeting TMED cargo receptors
Silvana Bazua-Valenti, Matthew R. Brown, Jason Zavras, Magdalena Riedl Khursigara, Elizabeth Grinkevich, Eriene-Heidi Sidhom, Keith H. Keller, Matthew Racette, Moran Dvela-Levitt, Catarina Quintanova, Hasan Demirci, Sebastian Sewerin, Alissa C. Goss, John Lin, Hyery Yoo, Alvaro S. Vaca Jacome, Malvina Papanastasiou, Namrata Udeshi, Steven A. Carr, Nina Himmerkus, Markus Bleich, Kerim Mutig, Sebastian Bachmann, Jan Halbritter, Stanislav Kmoch, Martina Živná, Kendrah Kidd, Anthony J. Bleyer, Astrid Weins, Seth L. Alper, Jillian L. Shaw, Maria Kost-Alimova, Juan Lorenzo B. Pablo, Anna Greka
Silvana Bazua-Valenti, Matthew R. Brown, Jason Zavras, Magdalena Riedl Khursigara, Elizabeth Grinkevich, Eriene-Heidi Sidhom, Keith H. Keller, Matthew Racette, Moran Dvela-Levitt, Catarina Quintanova, Hasan Demirci, Sebastian Sewerin, Alissa C. Goss, John Lin, Hyery Yoo, Alvaro S. Vaca Jacome, Malvina Papanastasiou, Namrata Udeshi, Steven A. Carr, Nina Himmerkus, Markus Bleich, Kerim Mutig, Sebastian Bachmann, Jan Halbritter, Stanislav Kmoch, Martina Živná, Kendrah Kidd, Anthony J. Bleyer, Astrid Weins, Seth L. Alper, Jillian L. Shaw, Maria Kost-Alimova, Juan Lorenzo B. Pablo, Anna Greka
View: Text | PDF
Research Article Nephrology

Disrupted uromodulin trafficking is rescued by targeting TMED cargo receptors

  • Text
  • PDF
Abstract

The trafficking dynamics of uromodulin (UMOD), the most abundant protein in human urine, play a critical role in the pathogenesis of kidney disease. Monoallelic mutations in the UMOD gene cause autosomal dominant tubulointerstitial kidney disease (ADTKD-UMOD), an incurable genetic disorder that leads to kidney failure. The disease is caused by the intracellular entrapment of mutant UMOD in kidney epithelial cells, but the precise mechanisms mediating disrupted UMOD trafficking remain elusive. Here, we report that transmembrane Emp24 protein transport domain–containing (TMED) cargo receptors TMED2, TMED9, and TMED10 bind UMOD and regulate its trafficking along the secretory pathway. Pharmacological targeting of TMEDs in cells, in human kidney organoids derived from patients with ADTKD-UMOD, and in mutant-UMOD-knockin mice reduced intracellular accumulation of mutant UMOD and restored trafficking and localization of UMOD to the apical plasma membrane. In vivo, the TMED-targeted small molecule also mitigated ER stress and markers of kidney damage and fibrosis. Our work reveals TMED-targeting small molecules as a promising therapeutic strategy for kidney proteinopathies.

Authors

Silvana Bazua-Valenti, Matthew R. Brown, Jason Zavras, Magdalena Riedl Khursigara, Elizabeth Grinkevich, Eriene-Heidi Sidhom, Keith H. Keller, Matthew Racette, Moran Dvela-Levitt, Catarina Quintanova, Hasan Demirci, Sebastian Sewerin, Alissa C. Goss, John Lin, Hyery Yoo, Alvaro S. Vaca Jacome, Malvina Papanastasiou, Namrata Udeshi, Steven A. Carr, Nina Himmerkus, Markus Bleich, Kerim Mutig, Sebastian Bachmann, Jan Halbritter, Stanislav Kmoch, Martina Živná, Kendrah Kidd, Anthony J. Bleyer, Astrid Weins, Seth L. Alper, Jillian L. Shaw, Maria Kost-Alimova, Juan Lorenzo B. Pablo, Anna Greka

×

Figure 5

Therapeutic targeting of TMEDs protects tubular epithelial cells from ER stress and apoptosis.

Options: View larger image (or click on image) Download as PowerPoint
Therapeutic targeting of TMEDs protects tubular epithelial cells from ER...
(A) Western blots of whole-kidney lysates from WT (UMOD+/+) and homozygous knockin (UMODC125R/C125R) mice treated with vehicle or BRD4780 (30 mg/kg) for 28 days. (B) Densitometric analysis of A. Data were normalized to the mean values of the vehicle-treated UMODC125R/C125R mice and analyzed via 2-way ANOVA with Bonferroni’s post hoc test. Data shown as mean ± SD, with each data point representing 1 mouse. (C) Western blots of whole-kidney lysates from 1 UMOD+/+ mouse and heterozygous knockin (UMOD+/C125R) mice treated as above. (D) Densitometric analysis of C. Data were normalized to the mean values of the vehicle-treated UMOD+/C125R mice and analyzed by Mann-Whitney test. Data shown as mean ± SD, with each data point representing 1 mouse. (E) Immunofluorescence images of TUNEL-stained kidney cortex from 10-month-old UMOD+/+ and UMOD+/C125R mice treated as above. Top panel: Brightfield is shown as the background, TUNEL+ cells are shown in red, and DAPI is shown in blue. Bottom panel: Same image as above without brightfield. Scale bars: 20 μm. (F) Quantification of TUNEL+ cells from at least 3 cortical fields per mouse analyzed by unpaired 2-tailed t test; data shown as mean ± SD, with each data point representing 1 mouse.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts